Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis

Eric J. Zeidman, Barbi Helfrick, Catherine Pollard, Ian M. Thompson

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: To determine whether or not patients with refractory interstitial cystitis who had failed conservative therapy might benefit from intravesical bacillus Calmette-Guérin (BCG) immunotherapy. Method: Five patients with refractory interstitial cystitis who had failed conservativetherapy underwent six weekly treatments with intravesical BCG. All 5 patients were evaluated before therapy and quarterly thereafter by water cystometry and symptom questionnaire. Results: The average number of medications used daily per patient decreased from 3.2 to 1.2 after therapy. Average volumes of both first desire to void and cystometric capacity doubled after BCG. Improvement in cystometric capacity, average daytime urinary frequency, nocturia, and global pain/discomfort were statistically significant (P = 0.0277, P = 0.0131, P = 0.0199, and P = 0.0317, respectively). Three patients experienced near total relief of their symptoms with six to twelve months' follow-up (average follow-up equals 33.6 weeks). Conclusions: Although the mechanism of action of BCG in interstitial cystitis is unknown,we recommend a double-blind placebo controlled trial to confirm these results and determine an optimal dosage and treatment schedule.

Original languageEnglish (US)
Pages (from-to)121-124
Number of pages4
JournalUrology
Volume43
Issue number1
DOIs
StatePublished - 1994

Fingerprint

Interstitial Cystitis
Immunotherapy
Bacillus
Nocturia
Therapeutics
Appointments and Schedules
Placebos
Pain
Water

ASJC Scopus subject areas

  • Urology

Cite this

Zeidman, E. J., Helfrick, B., Pollard, C., & Thompson, I. M. (1994). Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis. Urology, 43(1), 121-124. https://doi.org/10.1016/S0090-4295(94)80284-X

Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis. / Zeidman, Eric J.; Helfrick, Barbi; Pollard, Catherine; Thompson, Ian M.

In: Urology, Vol. 43, No. 1, 1994, p. 121-124.

Research output: Contribution to journalArticle

Zeidman, EJ, Helfrick, B, Pollard, C & Thompson, IM 1994, 'Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis', Urology, vol. 43, no. 1, pp. 121-124. https://doi.org/10.1016/S0090-4295(94)80284-X
Zeidman, Eric J. ; Helfrick, Barbi ; Pollard, Catherine ; Thompson, Ian M. / Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis. In: Urology. 1994 ; Vol. 43, No. 1. pp. 121-124.
@article{0fec0cbf420248f994787af0f5ffb20b,
title = "Bacillus Calmette-Gu{\'e}rin immunotherapy for refractory interstitial cystitis",
abstract = "Objective: To determine whether or not patients with refractory interstitial cystitis who had failed conservative therapy might benefit from intravesical bacillus Calmette-Gu{\'e}rin (BCG) immunotherapy. Method: Five patients with refractory interstitial cystitis who had failed conservativetherapy underwent six weekly treatments with intravesical BCG. All 5 patients were evaluated before therapy and quarterly thereafter by water cystometry and symptom questionnaire. Results: The average number of medications used daily per patient decreased from 3.2 to 1.2 after therapy. Average volumes of both first desire to void and cystometric capacity doubled after BCG. Improvement in cystometric capacity, average daytime urinary frequency, nocturia, and global pain/discomfort were statistically significant (P = 0.0277, P = 0.0131, P = 0.0199, and P = 0.0317, respectively). Three patients experienced near total relief of their symptoms with six to twelve months' follow-up (average follow-up equals 33.6 weeks). Conclusions: Although the mechanism of action of BCG in interstitial cystitis is unknown,we recommend a double-blind placebo controlled trial to confirm these results and determine an optimal dosage and treatment schedule.",
author = "Zeidman, {Eric J.} and Barbi Helfrick and Catherine Pollard and Thompson, {Ian M.}",
year = "1994",
doi = "10.1016/S0090-4295(94)80284-X",
language = "English (US)",
volume = "43",
pages = "121--124",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Bacillus Calmette-Guérin immunotherapy for refractory interstitial cystitis

AU - Zeidman, Eric J.

AU - Helfrick, Barbi

AU - Pollard, Catherine

AU - Thompson, Ian M.

PY - 1994

Y1 - 1994

N2 - Objective: To determine whether or not patients with refractory interstitial cystitis who had failed conservative therapy might benefit from intravesical bacillus Calmette-Guérin (BCG) immunotherapy. Method: Five patients with refractory interstitial cystitis who had failed conservativetherapy underwent six weekly treatments with intravesical BCG. All 5 patients were evaluated before therapy and quarterly thereafter by water cystometry and symptom questionnaire. Results: The average number of medications used daily per patient decreased from 3.2 to 1.2 after therapy. Average volumes of both first desire to void and cystometric capacity doubled after BCG. Improvement in cystometric capacity, average daytime urinary frequency, nocturia, and global pain/discomfort were statistically significant (P = 0.0277, P = 0.0131, P = 0.0199, and P = 0.0317, respectively). Three patients experienced near total relief of their symptoms with six to twelve months' follow-up (average follow-up equals 33.6 weeks). Conclusions: Although the mechanism of action of BCG in interstitial cystitis is unknown,we recommend a double-blind placebo controlled trial to confirm these results and determine an optimal dosage and treatment schedule.

AB - Objective: To determine whether or not patients with refractory interstitial cystitis who had failed conservative therapy might benefit from intravesical bacillus Calmette-Guérin (BCG) immunotherapy. Method: Five patients with refractory interstitial cystitis who had failed conservativetherapy underwent six weekly treatments with intravesical BCG. All 5 patients were evaluated before therapy and quarterly thereafter by water cystometry and symptom questionnaire. Results: The average number of medications used daily per patient decreased from 3.2 to 1.2 after therapy. Average volumes of both first desire to void and cystometric capacity doubled after BCG. Improvement in cystometric capacity, average daytime urinary frequency, nocturia, and global pain/discomfort were statistically significant (P = 0.0277, P = 0.0131, P = 0.0199, and P = 0.0317, respectively). Three patients experienced near total relief of their symptoms with six to twelve months' follow-up (average follow-up equals 33.6 weeks). Conclusions: Although the mechanism of action of BCG in interstitial cystitis is unknown,we recommend a double-blind placebo controlled trial to confirm these results and determine an optimal dosage and treatment schedule.

UR - http://www.scopus.com/inward/record.url?scp=0028167492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028167492&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(94)80284-X

DO - 10.1016/S0090-4295(94)80284-X

M3 - Article

VL - 43

SP - 121

EP - 124

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -